Regenerative Biotechnology
CTM Exosomas
Exosomes derived from mesenchymal stem cells with immunomodulatory and regenerative activity.
Injectable solution of mesenchymal stem cell–derived exosomes that modulate inflammatory response, promote tissue regeneration, and support control of autoimmune and degenerative processes.
Composition
Mesenchymal stem cell exosomes.
Pharmaceutical form
Injectable solution.
Presentation
Single-dose vial, 4 ml.
Therapeutic properties
Immunomodulatory and anti-inflammatory activity through gene regulation; promotes tissue regeneration and cellular repair in inflammatory, autoimmune, and chronic-degenerative processes.
- Modulation of inflammatory response.
- Reduction of autoimmune processes.
- Promotion of tissue regeneration.
- Support in chronic-degenerative diseases.
- Improvement in damaged tissue repair.
- Reduction of chronic inflammation.
- Adjuvant in oncological therapies.
- Application in dermato-aesthetic procedures.
Mechanism of action & Clinical data
Phagocytosed microvesicles release micro-RNA and proteins, regulating gene transcription, reducing pro-inflammatory pathways, and promoting an anti-inflammatory environment.
Indications
Adjuvant in chronic-degenerative and autoimmune diseases, persistent inflammation, and support during chemotherapy.
Administration
Slow intravenous administration diluted in 0.9% saline solution, not as a bolus.
Contraindications
Hypersensitivity to any component of the formula and diagnosis of neoplasia.
Storage
Refrigerate between 2–8 °C, protected from sunlight. Do not freeze.
